甲磺酸伊马替尼在系统性硬化症中是一种有前景的药物吗？

Is imatinib mesylate a promising drug in systemic sclerosis?

作者信息

van Daele P L A, Dik W A, Thio H B, van Hal P Th W, van Laar J A M, Hooijkaas H, van Hagen P M

机构信息

Erasmus MC, Rotterdam, The Netherlands.

出版信息

Arthritis Rheum. 2008 Aug;58(8):2549-52. doi: 10.1002/art.23648.

DOI:10.1002/art.23648

PMID:18668570

Abstract

A patient with therapy-resistant and progressive systemic sclerosis (SSc) with pulmonary involvement who was treated with imatinib mesylate is described herein. Prior to treatment, pulmonary fibroblasts obtained from the patient were cultured and incubated with imatinib mesylate. Preincubation of the fibroblasts for 16 hours with 2.5 microg/ml imatinib mesylate efficiently abrogated platelet-derived growth factor BB-induced fibroblast proliferation. Furthermore, transforming growth factor beta1-induced type I collagen gene transcription was blocked. During treatment, the patient's pulmonary involvement stabilized and her skin tightness improved. To our knowledge, this is the first report of a patient with therapy-refractory SSc responding to treatment with imatinib mesylate.

摘要

本文描述了一名患有治疗抵抗性和进行性系统性硬化症（SSc）且伴有肺部受累的患者，该患者接受了甲磺酸伊马替尼治疗。在治疗前，从该患者获取的肺成纤维细胞进行培养，并与甲磺酸伊马替尼一起孵育。用2.5微克/毫升甲磺酸伊马替尼对成纤维细胞进行16小时的预孵育可有效消除血小板衍生生长因子BB诱导的成纤维细胞增殖。此外，转化生长因子β1诱导的I型胶原基因转录也被阻断。在治疗期间，患者的肺部受累情况稳定，皮肤紧绷感有所改善。据我们所知，这是第一例对甲磺酸伊马替尼治疗有反应的难治性SSc患者的报告。